| Characteristic . | N (%)a . |
|---|---|
| Median age (range) | 56 (33-77) |
| Race/ethnicity | |
| Non–Hispanic White | 12 (43%) |
| Hispanic | 10 (36%) |
| African American | 4 (14%) |
| Asian | 2 (7%) |
| Histology at initial diagnosis | |
| IDC | 26 (92%) |
| ILC | 1 (4%) |
| Metaplastic | 1 (4%) |
| Tumor stage at initial diagnosis | |
| Stage I | 7 (25%) |
| Stage II | 7 (25%) |
| Stage III | 12 (43%) |
| Stage IV | 2 (7%) |
| Grade at initial diagnosis | |
| 1 | 1 (4%) |
| 2 | 6 (21%) |
| 3 | 19 (68%) |
| Unknown | 2 (7%) |
| AR status at time of metastasisb | |
| Positive | 9 (32%) |
| Negative | 18 (64%) |
| Not done | 1 (4%) |
| Prior surgery | 23 (82%) |
| Prior radiation | 19 (68%) |
| Prior lines for metastatic disease | |
| 0 | 16 (57%) |
| 1 | 9 (32%) |
| 2 | 3 (11%) |
| Site of metastasis | |
| Non–visceral | 15 (54%) |
| Liver | 4 (14%) |
| Lung | 9 (32%) |
| BRCA status | |
| BRCA1/2 positive | 4 (14%) |
| BRCA1/2 negative | 23 (82%) |
| BRCA1/2 not done | 1 (4%) |
| ECOG status | |
| 0 | 18 (64%) |
| 1 | 10 (36%) |
| Characteristic . | N (%)a . |
|---|---|
| Median age (range) | 56 (33-77) |
| Race/ethnicity | |
| Non–Hispanic White | 12 (43%) |
| Hispanic | 10 (36%) |
| African American | 4 (14%) |
| Asian | 2 (7%) |
| Histology at initial diagnosis | |
| IDC | 26 (92%) |
| ILC | 1 (4%) |
| Metaplastic | 1 (4%) |
| Tumor stage at initial diagnosis | |
| Stage I | 7 (25%) |
| Stage II | 7 (25%) |
| Stage III | 12 (43%) |
| Stage IV | 2 (7%) |
| Grade at initial diagnosis | |
| 1 | 1 (4%) |
| 2 | 6 (21%) |
| 3 | 19 (68%) |
| Unknown | 2 (7%) |
| AR status at time of metastasisb | |
| Positive | 9 (32%) |
| Negative | 18 (64%) |
| Not done | 1 (4%) |
| Prior surgery | 23 (82%) |
| Prior radiation | 19 (68%) |
| Prior lines for metastatic disease | |
| 0 | 16 (57%) |
| 1 | 9 (32%) |
| 2 | 3 (11%) |
| Site of metastasis | |
| Non–visceral | 15 (54%) |
| Liver | 4 (14%) |
| Lung | 9 (32%) |
| BRCA status | |
| BRCA1/2 positive | 4 (14%) |
| BRCA1/2 negative | 23 (82%) |
| BRCA1/2 not done | 1 (4%) |
| ECOG status | |
| 0 | 18 (64%) |
| 1 | 10 (36%) |
aMedian (range).
bAR positive, IHC AR ≥ 2+ and ≥30%; n (%).
| Characteristic . | N (%)a . |
|---|---|
| Median age (range) | 56 (33-77) |
| Race/ethnicity | |
| Non–Hispanic White | 12 (43%) |
| Hispanic | 10 (36%) |
| African American | 4 (14%) |
| Asian | 2 (7%) |
| Histology at initial diagnosis | |
| IDC | 26 (92%) |
| ILC | 1 (4%) |
| Metaplastic | 1 (4%) |
| Tumor stage at initial diagnosis | |
| Stage I | 7 (25%) |
| Stage II | 7 (25%) |
| Stage III | 12 (43%) |
| Stage IV | 2 (7%) |
| Grade at initial diagnosis | |
| 1 | 1 (4%) |
| 2 | 6 (21%) |
| 3 | 19 (68%) |
| Unknown | 2 (7%) |
| AR status at time of metastasisb | |
| Positive | 9 (32%) |
| Negative | 18 (64%) |
| Not done | 1 (4%) |
| Prior surgery | 23 (82%) |
| Prior radiation | 19 (68%) |
| Prior lines for metastatic disease | |
| 0 | 16 (57%) |
| 1 | 9 (32%) |
| 2 | 3 (11%) |
| Site of metastasis | |
| Non–visceral | 15 (54%) |
| Liver | 4 (14%) |
| Lung | 9 (32%) |
| BRCA status | |
| BRCA1/2 positive | 4 (14%) |
| BRCA1/2 negative | 23 (82%) |
| BRCA1/2 not done | 1 (4%) |
| ECOG status | |
| 0 | 18 (64%) |
| 1 | 10 (36%) |
| Characteristic . | N (%)a . |
|---|---|
| Median age (range) | 56 (33-77) |
| Race/ethnicity | |
| Non–Hispanic White | 12 (43%) |
| Hispanic | 10 (36%) |
| African American | 4 (14%) |
| Asian | 2 (7%) |
| Histology at initial diagnosis | |
| IDC | 26 (92%) |
| ILC | 1 (4%) |
| Metaplastic | 1 (4%) |
| Tumor stage at initial diagnosis | |
| Stage I | 7 (25%) |
| Stage II | 7 (25%) |
| Stage III | 12 (43%) |
| Stage IV | 2 (7%) |
| Grade at initial diagnosis | |
| 1 | 1 (4%) |
| 2 | 6 (21%) |
| 3 | 19 (68%) |
| Unknown | 2 (7%) |
| AR status at time of metastasisb | |
| Positive | 9 (32%) |
| Negative | 18 (64%) |
| Not done | 1 (4%) |
| Prior surgery | 23 (82%) |
| Prior radiation | 19 (68%) |
| Prior lines for metastatic disease | |
| 0 | 16 (57%) |
| 1 | 9 (32%) |
| 2 | 3 (11%) |
| Site of metastasis | |
| Non–visceral | 15 (54%) |
| Liver | 4 (14%) |
| Lung | 9 (32%) |
| BRCA status | |
| BRCA1/2 positive | 4 (14%) |
| BRCA1/2 negative | 23 (82%) |
| BRCA1/2 not done | 1 (4%) |
| ECOG status | |
| 0 | 18 (64%) |
| 1 | 10 (36%) |
aMedian (range).
bAR positive, IHC AR ≥ 2+ and ≥30%; n (%).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
